LIFE Successfully completes the first patient in the longevity trial after three months

11 Sep 2024 07:00 CEST

Bergen, Norway, 11 September 2024: Today, Lifecare ASA (LIFE), a clinical
stage medical sensor company developing the next generation Continuous Glucose
Monitor (CGM), can announce the successful completion of the first veterinary
patient of the longevity trials as per the original study protocol.

Reference is made to the press release from 18 June 2024 when the company
announced the initiation of trials using wireless readout technology.
Yesterday, Lifecare's veterinary team at Norwegian University of Life Sciences
(NMBU), removed the implant from the dog Elli after 12 weeks, in accordance
with the regulatory approved protocol. The reports from our team confirm that
Elli is in good health, showing no signs of discomfort related to the implant.

Lifecare considered extending the study, and while this was approved by the
Norwegian authorities, it was deemed most valuable to remove the implant for
inspection after 12 weeks, as per the original study protocol. Lifecare's team
will now review the initial results and investigate additional data, for a
thorough analysis of both the sensor and the surrounding tissue after
implantation.

- The 12-week lifespan is remarkable compared to today's glucose monitors. We
are extremely pleased to have successfully completed the first patient in the
longevity study at NMBU, with the sensor performing exactly as expected.
Importantly, there have been no negative effects on the body, skin or tissue.
Previous in-vitro studies have confirmed a sensor lifespan of up to six
months, and this study further validates both the Sencell sensor's
functionality and its biocompatibility, demonstrating that it is safe and
reliable for long-term use says CEO Joacim Holter at Lifecare ASA.

- Retrieving the sensor from Elli now provides a valuable opportunity to
further understand the sensor's characteristics and identify potential areas
for improvement. During the removal process, a comprehensive visual
examination of both the patient and the sensor was performed, revealing no
signs of abnormalities. Additionally, a biopsy will be performed to evaluate
any potential tissue reactions or impact, ensuring the sensor's
biocompatibility, says Managing Director Jo Amundstad at Lifecare Veterinary.

The data collected over three months, along with the sensor analysis, will be
examined in Lifecare's Iaboratories in Germany.

- We are proud to demonstrate that our Sencell sensor exceeds the operational
lifespan of all major CGM systems in the market by a factor of six or more.
These longevity trials, now underway at NMBU, are bringing the competitive
advantages of the Sencell sensor to light. We have consistently demonstrated
that this technology will be highly beneficial for people living with
diabetes, says Holter.

The primary goal of the first sensor in the longevity trial was to investigate
and confirm its operational lifespan in a long-term perspective. The main
expectations were to validate the sensor's durability and ensure its
biocompatibility, confirming that no adverse reactions occur over time.

- We will soon start preparations to enroll additional patients in the study
to validate these initial findings and expand the focus beyond sensor
functionality. Our goal is to concentrate more on glucose readings from both
healthy dogs and cats with diabetes. This approach will help us gain an even
deeper understanding of the sensor's performance in real world conditions,
says Managing Director Jo Amundstad at Lifecare Veterinary.

About us
Lifecare ASA is a clinical stage medical sensor company developing technology
for sensing and monitoring of various body analytes. Lifecare's main focus is
to bring the next generation of Continuous Glucose Monitoring ("CGM") systems
to market. Lifecare enables osmotic pressure as sensing principle, combined
with the ability to manipulate Nano-granular Tunnelling Resistive sensors
("NTR") on the sensor body for read-out of pressure variations. Lifecare's
sensor technology is referred to as "Sencell" and is suitable for identifying
and monitoring the occurrence of a wide range of analytes and molecules in the
human body and in pets.

Contacts
For further information, please contact:

Joacim Holter, CEO, joacim.holter@lifecare.no, +47 40 05 90 40

Renete Kaarvik, CFO, renete.kaarvik@lifecare.no, +47 94 83 82 42

More information:
Access the news on Oslo Bors NewsWeb site

627455_LIFE Successfully completes the first patient in the longevity trial after three months.pdf